The Hidden Root Cause Behind Histamine Overload and MCAS: What Your Gut’s Bacterial Toxins Are Doing to Your Immune System
- Ann Gunn
- 3 days ago
- 14 min read
If you’ve been struggling with histamine intolerance, mast cell activation syndrome (MCAS), or a collection of seemingly unrelated symptoms — flushing, itching, brain fog, bloating, heart palpitations, anxiety, or chronic fatigue — there’s a good chance your gut is at the center of the story. Not just the symptoms in your gut, but what’s leaking out of it.
In my practice, working with clients navigating chronic illness, one of the most consistent findings I see early on is a dysbiotic gut — a gut microbiome that is out of balance, inflamed, and compromised at the barrier level. And one of the most overlooked contributors to histamine overload and MCAS-like presentations is something called lipopolysaccharide, or LPS.
This article is going to go deep. I want you to understand the mechanism, the research, and the many tools available to address it — including some powerful CellCore Biosciences protocols and their newly launched CoreMend GI, which I’m genuinely excited about.
Let’s dig in.
What Is LPS and Why Should You Care?
Lipopolysaccharide (LPS) is a structural component found on the outer membrane of gram-negative bacteria — the type that make up a significant portion of your gut microbiome. Under normal circumstances, LPS stays right where it belongs: inside your intestinal tract. Your gut epithelium acts as a physical barrier, and your immune system manages any trace amounts that make it through.
But when that barrier becomes compromised — what we commonly call leaky gut, or increased intestinal permeability — LPS molecules begin crossing into the bloodstream and lymphatic system in quantities the body was never designed to handle. This is known as metabolic endotoxemia, and the research literature over the past two decades has increasingly linked it to a remarkable range of chronic conditions.
Here’s what happens when LPS gets where it shouldn’t be:
LPS binds to TLR4 receptors (Toll-Like Receptor 4) on immune cells, and critically, on mast cells — the tissue-resident immune cells that are the primary drivers of histamine release. When LPS activates TLR4 on a mast cell, that mast cell degranulates, releasing histamine, tryptase, prostaglandins, and a cascade of inflammatory mediators. Simultaneously, LPS suppresses diamine oxidase (DAO) — the primary enzyme responsible for breaking down histamine in the intestinal tract.
The result is a double hit: more histamine being produced and less histamine being broken down. Over time, if the LPS burden remains elevated, the body settles into a state of chronic mast cell hyperreactivity. This is the LPS → MCAS connection that is increasingly recognized by researchers, even if it remains underdiagnosed in clinical settings.
The Leaky Gut Connection: Zonulin, Tight Junctions, and the Gateway for LPS
The gut epithelium is only one cell thick in most areas. It is held together by protein structures called tight junctions — literally the physical seals between cells that determine what gets through and what doesn’t. When tight junctions are disrupted, the gate opens.
Zonulin is a protein produced by intestinal cells that regulates the opening and closing of tight junctions. In a healthy gut, zonulin activity is balanced. In a dysbiotic, inflamed gut, zonulin becomes chronically elevated — essentially holding those tight junctions open. Elevated zonulin is one of the most clinically measurable markers of leaky gut, and it creates the conditions for sustained LPS translocation.
What disrupts tight junctions and drives zonulin up in the first place? The usual suspects are all too familiar in our modern world: dysbiosis (overgrowth of pathogenic or gram-negative bacteria), dietary gluten, chronic stress, NSAID use, alcohol, mycotoxin exposure, and infections. For most of my clients dealing with chronic illness, multiple factors have been at play for years before they arrive at my door.
Healing the System: A Multi-Layer Approach
Addressing LPS overload and the histamine/MCAS cascade it drives is not a single supplement fix. Based on both the research literature and years of clinical experience, this requires a multi-layer strategy that works simultaneously on several fronts:
1. Neutralizing and binding LPS already in the gut lumen
2. Sealing the gut barrier and restoring tight junction integrity
3. Reducing the gram-negative bacterial load that produces LPS
4. Blocking TLR4/mast cell reactivity to LPS
5. Restoring histamine-clearing enzyme activity
6. Rebuilding a healthy, protective microbiome
Let’s walk through each layer with the science and the tools I use.
Layer 1: Sealing the Gut Barrier
You can’t stop the flood until you fix the leak. Restoring gut barrier integrity is the foundational first step.
Akkermansia muciniphila
Akkermansia is a mucin-dwelling bacterium that acts as an architect of your gut’s first line of defense — the mucin layer. Research from Patrice Cani’s group and others has shown that Akkermansia directly stimulates production of the mucin proteins (Muc2, Muc5) that form the gel-like protective layer lining the gut wall. It reduces zonulin, and upregulates tight junction proteins like claudin-3 and occludin. In metabolic endotoxemia studies, restoring Akkermansia populations has been associated with reductions in circulating LPS of up to 50%.
Interestingly, pasteurized (heat-killed) Akkermansia appears to be equally effective — or more so in some studies — than live strains, due to a specific outer membrane protein called Amuc_1100 that directly communicates with the gut epithelium.
Fulvic and Humic Acids
This is where CellCore’s foundational technology comes in. The BioActive Carbon® Technology used across CellCore’s product line is a proprietary blend of fulvic acids derived from ancient organic matter. Fulvic acid has been shown in research to directly bind LPS molecules in the gut lumen — essentially chelating the endotoxin before it can be absorbed. Humic substances stimulate tight junction protein expression, including ZO-1 and occludin, and have demonstrated anti-histamine properties via mast cell stabilization independent of their LPS-binding effects.
This is one of the reasons I find CellCore’s approach so foundational — the BioActive Carbon technology isn’t just a delivery vehicle; it’s actively participating in endotoxin management.
Zinc Carnosine (PepZin GI)
One of the most well-researched mucosal repair agents available, zinc carnosine has been shown in clinical trials to restore tight junction integrity, reduce zonulin levels, and inhibit LPS-driven NF-κB activation in epithelial cells. Zinc is also a critical cofactor for alkaline phosphatase — the endogenous enzyme that detoxifies LPS by dephosphorylating its lipid A component.
L-Glutamine
Glutamine is the primary fuel source for enterocytes — the cells lining your gut. Deficiency creates conditions for tight junction breakdown almost immediately. L-glutamine supplementation has been shown to reduce expression of myosin light chain kinase (MLCK), the molecular pathway through which LPS actually opens tight junctions. Studies consistently show reduction in zonulin and normalization of intestinal permeability markers with glutamine supplementation.
Butyrate / Sodium Butyrate
Butyrate is a short-chain fatty acid produced when beneficial gut bacteria ferment dietary fiber. It is both the primary fuel for colonocytes and a powerful epigenetic regulator (HDAC inhibitor) that upregulates tight junction protein gene expression. Butyrate also directly suppresses histidine decarboxylase — the enzyme that converts histidine into histamine. Restoring butyrate levels through diet and supplementation is one of the highest-leverage interventions available for both leaky gut and histamine overload simultaneously.
Layer 2: Binding and Neutralizing LPS
Lactoferrin
Lactoferrin is a glycoprotein found in high concentrations in colostrum and breast milk. It binds the lipid A portion of LPS with extraordinary affinity, directly neutralizing endotoxin before it can activate immune receptors. Oral lactoferrin has been shown in clinical trials to reduce serum endotoxin and circulating inflammatory markers. It also reduces mast cell degranulation and histamine release in LPS-stimulated models.
Bovine Colostrum
Colostrum is rich in secretory IgA (sIgA) — the gut’s primary antibody, which directly binds and neutralizes LPS in the lumen. It also contains proline-rich polypeptides (PRPs) that have been shown to modulate mast cell activity. In addition to lactoferrin, colostrum contains a range of growth factors that directly support mucosal healing.
Saccharomyces boulardii
This beneficial yeast is one of the most evidence-backed interventions for endotoxemia. It produces a protease that cleaves and inactivates LPS directly in the gut lumen, stimulates sIgA production, and has been shown in clinical trials to significantly reduce zonulin levels. If there is one probiotic-category supplement I consider near-essential for leaky gut and high LPS burden, S. boulardii is it.
Layer 3: Targeted Probiotics for Microbiome Restoration
Not all probiotics are equal when it comes to LPS and histamine. The strains that matter most here include:
Lactobacillus rhamnosus GG — Reduces intestinal permeability via upregulation of ZO-1 and occludin; shown to reduce LPS-induced mast cell histamine release.
Lactobacillus plantarum 299v — Has direct LPS-binding capacity on its cell wall, reducing both translocation and TLR4 signaling downstream.
Bifidobacterium longum & B. infantis — Shown to reduce histamine sensitivity and downregulate mast cell reactivity; produce acetate that feeds the mucosal barrier.
Lactobacillus reuteri — Produces reuterin, which selectively suppresses gram-negative bacteria (the LPS producers); also modulates histamine via tolerogenic immune pathways.
Bacillus coagulans & B. subtilis — Spore-forming strains with excellent survivability to the colon; produce enzymes that degrade LPS and stimulate butyrate-producing commensals.
Layer 4: Prebiotic and Dietary Strategies
Rebuilding a microbiome that keeps gram-negative overgrowth in check requires feeding the right bacteria consistently.
Resistant Starch (RS2/RS3) is the most potent dietary stimulus for butyrate-producing bacteria like Faecalibacterium prausnitzii and Roseburia. F. prausnitzii is one of the most anti-inflammatory bacteria in the gut and is inversely correlated with LPS translocation markers.
PHGG (Partially Hydrolyzed Guar Gum) is a prebiotic fiber with strong clinical evidence for selectively feeding Akkermansia and butyrate producers, while also reducing intestinal transit irregularities that can worsen LPS accumulation.
Beta-glucans from oats or mushrooms bind LPS in the gut lumen, compete at TLR4 decoy receptors, and have been shown to reduce serum LPS and CRP in metabolic endotoxemia studies.
Arabinogalactan is a highly selective prebiotic for Lactobacillus and Bifidobacterium species, and also stimulates sIgA production — the gut’s primary LPS-neutralizing antibody.
Layer 5: Reducing Gram-Negative Bacterial Overgrowth
You can’t fully resolve an LPS burden without addressing the source.
Berberine is one of the most researched natural antimicrobials with selectivity against gram-negative bacteria. It also directly blocks TLR4/NF-κB signaling downstream of LPS and activates AMPK, which independently reduces intestinal permeability. Clinical trials have demonstrated reductions in circulating LPS and inflammatory cytokines with berberine supplementation.
Allicin (from garlic) disrupts gram-negative biofilms and directly suppresses LPS production at its source. It also has mast cell stabilizing properties.
Mimosa pudica Seed — CellCore’s Para 1 is made from 100% pure Mimosa pudica seed, which becomes gelatinous and sticky as it moves through the GI tract. This supports the removal of intestinal buildup and unwanted organisms, directly reducing the gram-negative burden that produces LPS. Para 1 is foundational in CellCore’s protocol lineup and is one of the first tools I reach for with clients whose gut burden is high.
Rifaximin (a medical intervention) is a non-absorbed antibiotic highly effective against gram-negative SIBO. It also reduces zonulin and intestinal permeability via pregnane X receptor activation — independent of its antimicrobial effect.
Layer 6: Blocking TLR4 and Stabilizing Mast Cells
Even while the underlying gut is being repaired, it helps enormously to reduce the reactivity of the immune system to the LPS that is still circulating.
Palmitoylethanolamide (PEA) is an endocannabinoid-like compound that acts on PPAR-α receptors to directly downregulate mast cell degranulation. It is one of the most evidence-backed natural mast cell stabilizers available, and has been shown to reduce LPS-stimulated release of histamine, tryptase, and inflammatory mediators.
Luteolin is a flavonoid that inhibits TLR4 signaling directly at the receptor level, downregulates NF-κB activation, and is a potent mast cell stabilizer. It synergizes well with PEA.
Quercetin inhibits mast cell histamine release at multiple steps, blocks NF-κB and LPS-driven cytokine release, inhibits histidine decarboxylase, and upregulates ZO-1 tight junction proteins. It is one of the most versatile compounds available for this presentation.
Curcumin (liposomal or with piperine) blocks formation of the TLR4-MD2 receptor complex — essentially preventing LPS from docking at its primary receptor. Shown to reduce both intestinal permeability and LPS-driven inflammatory cascades in multiple models.
Modified Citrus Pectin (MCP) deserves special mention here. MCP acts as a galectin-3 inhibitor — galectin-3 being a protein that amplifies LPS-driven inflammation and mast cell activation significantly. MCP also functions as a gentle prebiotic and has solid support in the endotoxemia literature.
Layer 7: Restoring Histamine Clearance
While all of the above addresses the root cause, supporting the body’s ability to clear histamine directly provides important symptomatic relief during the healing process.
DAO Enzyme Supplementation replaces the diamine oxidase activity that chronic LPS exposure has suppressed. It directly breaks down ingested histamine before it can be absorbed.
Vitamin B6 (as P5P) is an essential cofactor for DAO enzyme activity. LPS-driven inflammation depletes B6 — supplementation is often necessary to restore functional DAO activity.
Copper is required for DAO function and is frequently depleted in chronic inflammatory states.
Methylation Support (B12, methylfolate, magnesium, TMG) supports the HNMT (histamine N-methyltransferase) pathway — the intracellular histamine-clearing enzyme. Individuals with MTHFR or COMT variants often have impaired HNMT function, compounding the MCAS presentation significantly.
Introducing CellCore’s CoreMend GI: A Five-Pillar Approach in One Daily Stick
I want to talk about a product that CellCore just launched this month, because it addresses this entire conversation in a remarkably elegant way.
CoreMend GI is described as a “five-pillar daily gut restoration formula” — built on the principle that gut dysfunction is never just one thing. The five pillars it targets simultaneously are:
1. The gut barrier — fortified at the cellular, structural, and protective levels
2. The mucosal lining — a five-botanical complex coats, calms, and protects the GI lining
3. The microbiome — the CoreMend Fiber Blend nourishes beneficial microbes with prebiotic fibers
4. The gut-immune interface — supporting immune balance at the mucosal level
5. The gut-brain axis — the CoreMend GI Probiotic Blend restores the gut-brain connection from three angles: microbial signals, neuroactive compounds, and nervous system tone
Like all CellCore formulas, CoreMend GI is formulated with BioActive Carbon® Technology — meaning the fulvic acid matrix not only enhances delivery and bioavailability of the active ingredients, but is itself participating in LPS binding and cellular repair.
What excites me about CoreMend GI in the context of the LPS → histamine → MCAS picture is that it addresses both the structural barrier work (mucosa, tight junctions) and the microbiome restoration and the gut-brain signaling that is so frequently disrupted in chronic illness — all in a once-daily convenient format. This makes it a strong foundational piece for clients who are working on reducing their endotoxin burden.
You can find CoreMend GI and other CellCore products mentioned in this article directly through my CellCore practitioner account at:
[CellCore Biosciences Practitioner Portal] Enter Patient Direct Code = Ea2HQJXv
Other Key CellCore Products in This Protocol Space
Beyond CoreMend GI, here are the CellCore products I frequently use with clients navigating LPS overload and gut-driven MCAS:
BioToxin Binder — A BioActive Carbon-based binder containing fulvic and humic acids that binds endotoxins (including LPS) in the gut lumen, preventing reabsorption and supporting their clearance through the digestive tract. This is often foundational in Phase 1 of any gut restoration work.
Para 1 (Mimosa pudica Seed) — Directly targets the gram-negative organisms producing LPS, while its sticky, gel-forming action physically sweeps the GI tract. Essential for reducing the LPS source load.
CT-Biotic — CellCore’s probiotic formulation, pairing well with CoreMend GI or used independently to support microbiome diversity and barrier-supporting probiotic populations.
Intestinal Permeability Kit — A bundle designed specifically for leaky gut support, combining Para 1, additional gut support herbs, and BioActive Carbon Technology. This kit targets gut permeability directly and is an excellent starting point for clients whose primary issue is a compromised barrier.
Advanced TUDCA — While not directly an LPS intervention, TUDCA supports liver and bile flow, which is critical for processing the LPS and endotoxins that do make it into circulation. A congested liver prolongs the inflammatory burden significantly.
The Sequence Matters: How I Approach This Clinically
One thing I want to emphasize from clinical experience: the order of interventions matters.
Aggressively killing gram-negative bacteria before the gut barrier is sealed can cause a significant die-off reaction — a transient spike in LPS release as bacteria die and release their endotoxin load. This can dramatically worsen histamine symptoms in the short term. This is sometimes called a Herxheimer reaction, and it’s real.
The general principle I follow in practice:
1. Open drainage pathways first (liver, bile, lymph — this is where CellCore’s drainage-first philosophy shines)
2. Bind existing toxins and LPS (BioToxin Binder, fulvic acid, MCP)
3. Begin sealing the gut barrier (CoreMend GI, L-glutamine, zinc carnosine, butyrate)
4. Gently reduce gram-negative overgrowth (Para 1, berberine, targeted botanicals)
5. Actively rebuild the microbiome (CoreMend GI fiber and probiotic blends, resistant starch, targeted probiotic strains)
6. Support histamine clearance throughout (DAO enzyme, P5P, methylation support)
This isn’t a one-month protocol. For clients with significant chronic illness, rebuilding the gut to the point where LPS-driven mast cell activation is resolved can take 6–12 months of consistent work. But the trajectory — the progressive reduction in reactivity, the improvements in energy, the calming of histamine symptoms — is consistently rewarding to witness.
A Note on Testing:
If you want to know where you stand with LPS burden clinically, there are markers worth discussing with your healthcare provider:
- LPS-Binding Protein (LBP) — A liver-produced acute phase protein that rises in proportion to circulating LPS
- Soluble CD14 (sCD14) — A co-receptor for LPS; elevated levels indicate active LPS translocation
- Zonulin (serum or stool) — The most accessible clinical marker of tight junction permeability
- Histamine and DAO levels — Can confirm the LPS → enzyme suppression → histamine accumulation picture
- Stool microbiome testing — To assess gram-negative overgrowth, butyrate producers, and Akkermansia abundance directly
The Bottom Line
Histamine overload and MCAS are not random. For a very significant subset of people dealing with these conditions, the root is in the gut — specifically in a dysbiotic, permeable gut that is allowing LPS to flood the immune system, activate mast cells, suppress histamine-clearing enzymes, and drive a chronic inflammatory state that touches virtually every system in the body.
The good news is that this mechanism is reversible. The gut has remarkable regenerative capacity when given the right support. The research is increasingly clear on what works: sealing the barrier, binding and clearing endotoxin, reducing gram-negative overgrowth, restoring the microbiome, and supporting histamine clearance throughout.
If you’re dealing with histamine intolerance, MCAS, or chronic gut issues and want personalized guidance on navigating this process, I work with clients one-on-one.
You can also access CellCore products through my:
[Click here for my CellCore Practitioner Portal] Enter Patient Direct Code = Ea2HQJXv
For access to my Practitioner Supplement Dispensary portals, including FullScript, for many of the other products mentioned in this article, see my Resources Page: [Click here for my Resources page]
Your gut — and your immune system — can heal. Let’s do the work.
References:
The following peer-reviewed literature and scientific sources informed this article:
1. Cani PD, et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56(7), 1761–1772.
2. Cani PD, et al. (2009). Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut, 58(8), 1091–1103.
3. Plovier H, et al. (2017). A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine, 23(1), 107–113.
4. Fasano A. (2012). Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clinical Gastroenterology and Hepatology, 10(10), 1096–1100.
5. Theoharides TC, et al. (2012). Mast cells and inflammation. Biochimica et Biophysica Acta, 1822(1), 21–33.
6. Farhadi A, et al. (2003). Intestinal barrier: an interface between health and disease. Journal of Gastroenterology and Hepatology, 18(5), 479–497.
7. Di Nardo G, et al. (2014). Mast cell involvement in LPS-induced gut permeability and endotoxemia. Neurogastroenterology & Motility, 26(5), 619–629.
8. Nakajima S, et al. (2011). Zinc L-carnosine inhibits LPS-induced intestinal permeability in Caco-2 cells via NF-κB suppression. Digestive Diseases and Sciences, 56(2), 353–360.
9. Suzuki T, & Hara H. (2011). Role of flavonoids in intestinal tight junction regulation. Journal of Nutritional Biochemistry, 22(5), 401–408.
10. Ukena SN, et al. (2007). Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE, 2(12), e1308.
11. Patel RM, & Denning PW. (2013). Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what the science says. Clinics in Perinatology, 40(1), 11–25.
12. Koh A, et al. (2016). From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 165(6), 1332–1345.
13. Legrand D. (2012). Lactoferrin, a key molecule in immune and inflammatory processes. Biochemistry and Cell Biology, 90(3), 252–268.
14. Mohan M, et al. (2021). Therapeutic potential of berberine as an anti-inflammatory and anti-infective agent: an overview. Bioorganic & Medicinal Chemistry Letters, 30(23), 127554.
15. Vanheel H, et al. (2014). Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut, 63(2), 262–271.
16. Bischoff SC, et al. (2014). Intestinal permeability — a new target for disease prevention and therapy. BMC Gastroenterology, 14, 189.
17. Forsyth CB, et al. (2009). Alcohol stimulates activation of Snail, epidermal growth factor receptor signaling, and biomarkers of epithelial–mesenchymal transition in colon and breast cancer cells. Alcoholism: Clinical and Experimental Research.
18. Mooteri S, et al. (2004). Modified citrus pectin as a galectin-3 inhibitor in the context of inflammatory signaling. Journal of the National Cancer Institute, 96(18).
19. Guerrini V, & Bhatt DL. (2016). Endotoxemia and metabolic disease: the role of LPS. Current Opinion in Lipidology, 27(5), 432–440.
20. Theoharides TC, Tsilioni I, Hua J. (2019). Potential role of mast cells in COVID-19, post-COVID disease, and vaccine hypersensitivity. International Journal of Molecular Sciences, 22(3), 1132.
Disclaimer:
This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects current research literature and the clinical experience of the author who holds a Master's of Science in Holistic Nutrition; it is not a substitute for the advice of a qualified healthcare provider. If you are dealing with a chronic illness, suspected MCAS, histamine intolerance, or gut dysbiosis, please work with a licensed medical professional. Individual results vary.
Statements regarding CellCore Biosciences products have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Some links in this article may be affiliate or practitioner referral links. The author uses and recommends these products based on clinical experience and research; no sponsorship influenced the content of this article.
© [thedetoxprotocols.com](https://www.thedetoxprotocols.com) | All rights reserved.
Comments